{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:43:07Z","timestamp":1765737787651,"version":"3.48.0"},"reference-count":21,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T00:00:00Z","timestamp":1715731200000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Rotterdam Eczema Study was an observational cohort study with an embedded pragmatic randomised controlled open-label trial. It was conducted in children with atopic dermatitis (AD) in the Dutch primary care system. The objective of the trial was to determine whether a potent topical corticosteroid (TCS) is more effective than a low-potency TCS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We are aiming to communicate transparently about the poor recruitment for the trial part and to explore the reasons why recruitment was weak.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>We used a survey to find out what patients in the cohort did when they experienced a flare-up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Descriptive statistics were used to present the baseline characteristics of participants in the trial and the results of the survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 367 patients were included in the cohort. Of these, 32 were randomly assigned to a trial treatment; they had a median age of 4.0 years (IQR 2.0\u20139.8). A total of 69 of the 86 children (80.2%) who could participate in the survey responded. 39 (56.5%) suffered a flare-up during the follow-up (making them potentially eligible for inclusion in the trial). 26 out of 39 (66.7%) increased their use of an emollient and\/or TCS themselves. Only 12 of the 39 (30.7%) contacted their general practitioner (GP) as instructed in the study protocol, but 8 out of these 12 did not meet the inclusion criteria for the trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The main reason why cohort participants did not take part in the trial was that they did not contact their GPs when they experienced an AD flare-up. Furthermore, the majority of patients who contacted their GPs did not match the inclusion criteria of the trial. We expect that the lessons learnt from this study will be useful when developing future studies of children with AD in primary care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-078942","type":"journal-article","created":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T02:30:14Z","timestamp":1715826614000},"page":"e078942","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Reasons for unsuccessful recruitment of children with atopic dermatitis in primary care in the Netherlands to a cohort study with an embedded pragmatic, randomised controlled open-label trial: a survey"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9516-8193","authenticated-orcid":false,"given":"Karlijn F","family":"van Halewijn","sequence":"first","affiliation":[{"name":"Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur M","family":"Bohnen","sequence":"additional","affiliation":[{"name":"Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne G M A","family":"Pasmans","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick J E","family":"Bindels","sequence":"additional","affiliation":[{"name":"Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6988-0179","authenticated-orcid":false,"given":"Gijs","family":"Elshout","sequence":"additional","affiliation":[{"name":"Department of General Practice, Erasmus MC University Medical Center, Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,5,15]]},"reference":[{"key":"2025121410421328000_14.5.e078942.1","unstructured":"van der MW , S SL , Schellevis FG , et al . Tweede Nationale Studie Naar Ziekten en Verrichtingen in de Huisartsenpraktijk. In: Het kind in de huisartsenpraktijk. Utrecht, Rotterdam: NIVEL, 2005."},{"key":"2025121410421328000_14.5.e078942.2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0182664","article-title":"Atopic children and use of prescribed medication: a comprehensive study in general practice","volume":"12","author":"Pols","year":"2017","journal-title":"PLOS ONE"},{"key":"2025121410421328000_14.5.e078942.3","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1111\/jdv.18185","article-title":"Care pathways in Atopic dermatitis: a retrospective population-based cohort study","volume":"36","author":"von Kobyletzki","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025121410421328000_14.5.e078942.4","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1684\/ejd.2022.4197","article-title":"Recommendations for Emollients, bathing and topical corticosteroids for the treatment of Atopic dermatitis: a systematic review of guidelines","volume":"32","author":"Van Halewijn","year":"2022","journal-title":"Eur J Dermatol"},{"key":"2025121410421328000_14.5.e078942.5","doi-asserted-by":"crossref","unstructured":"Lax SJ , Harvey J , Axon E , et al . Strategies for using topical corticosteroids in children and adults with Eczema. Cochrane Database Syst Rev 2022;3. doi:10.1002\/14651858.CD013356.pub2","DOI":"10.1002\/14651858.CD013356.pub2"},{"key":"2025121410421328000_14.5.e078942.6","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-027239","article-title":"Different potencies of topical corticosteroids for a better treatment strategy in children with Atopic dermatitis (the Rotterdam Eczema study): protocol for an observational cohort study with an embedded randomised open-label controlled trial","volume":"9","author":"van Halewijn","year":"2019","journal-title":"BMJ Open"},{"key":"2025121410421328000_14.5.e078942.7","doi-asserted-by":"crossref","DOI":"10.1186\/1745-6215-7-9","article-title":"What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies","volume":"7","author":"McDonald","year":"2006","journal-title":"Trials"},{"key":"2025121410421328000_14.5.e078942.8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000013.pub6"},{"key":"2025121410421328000_14.5.e078942.9","first-page":"240","article-title":"NHG-Standaard Eczeem","volume":"5","author":"Dirven-Meijer","year":"2014","journal-title":"Huisarts Wet"},{"key":"2025121410421328000_14.5.e078942.10","doi-asserted-by":"publisher","DOI":"10.1080\/000155599750010256"},{"key":"2025121410421328000_14.5.e078942.11","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15179"},{"key":"2025121410421328000_14.5.e078942.12","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-023-02936-1","article-title":"Providing multimedia information to children and young people increases recruitment to trials: pre-planned meta-analysis of Swats","volume":"21","author":"Knapp","year":"2023","journal-title":"BMC Med"},{"key":"2025121410421328000_14.5.e078942.13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jclinepi.2019.12.001","article-title":"Recruitment through media and general practitioners resulted in comparable samples in an RCT on Incontinence","volume":"119","author":"van der Worp","year":"2020","journal-title":"J Clin Epidemiol"},{"key":"2025121410421328000_14.5.e078942.14","doi-asserted-by":"crossref","unstructured":"Baker A , Mitchell EJ , Thomas KS . A practical guide to implementing a successful social media recruitment strategy: lessons from the Eczema monitoring online trial. Trials 2022;23. doi:10.1186\/s13063-022-06839-z","DOI":"10.1186\/s13063-022-06839-z"},{"key":"2025121410421328000_14.5.e078942.15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(22)02597-1","article-title":"Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial","volume":"401","author":"Butler","year":"2023","journal-title":"The Lancet"},{"key":"2025121410421328000_14.5.e078942.16","unstructured":"van KF , et al . Atopic dermatitis in children in the general population: baseline characteristics, medication use, and severity measures in the Rotterdam Eczema study. Dermatitis 2023."},{"key":"2025121410421328000_14.5.e078942.17","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-045343"},{"key":"2025121410421328000_14.5.e078942.18","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1186\/s13063-021-05818-0","article-title":"Exploring reasons for recruitment failure in clinical trials: a qualitative study with clinical trial Stakeholders in Switzerland, Germany, and Canada","volume":"22","author":"Briel","year":"2021","journal-title":"Trials"},{"key":"2025121410421328000_14.5.e078942.19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/srt.13136","article-title":"Mild to moderate Atopic dermatitis severity can be reliably assessed using Smartphone-photographs taken by the patient at home: a validation study","volume":"28","author":"Ali","year":"2022","journal-title":"Skin Res Technol"},{"key":"2025121410421328000_14.5.e078942.20","doi-asserted-by":"crossref","unstructured":"Avi\u00ebl Ragamin RS , Schuttelaar M-L , Nouwen AEM , et al . Remote severity assessment in Atopic Dermatitis: validity and reliability of the remote EASI and SA-EASI. Acta Derm Venereol 2022;9. doi:10.1016\/j.jdin.2023.07.019","DOI":"10.1016\/j.jdin.2023.07.019"},{"key":"2025121410421328000_14.5.e078942.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2016.07.016"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-078942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:42:22Z","timestamp":1765737742000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-078942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,15]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bmjopen-2023-078942"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-078942","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}